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A goal of the COG Ewing Sarcoma (ES) Biology Committee is enabling identification of
reliable biomarkers that can predict treatment response and outcome through the use of
prospectively collected tissues and correlative studies in concert with COG therapeutic
studies. In this report, we aim to provide a concise review of the most well-characterized
prognostic biomarkers in ES, and to provide recommendations concerning design and
implementation of future biomarker studies. Of particular interest and potentially high clin-
ical relevance are studies of cell-cycle proteins, sub-clinical disease, and copy number
alterations. We discuss findings of particular interest from recent biomarker studies and
examine factors important to the success of identifying and validating clinically relevant
biomarkers in ES. A number of promising biomarkers have demonstrated prognostic sig-
nificance in numerous retrospective studies and now need to be validated prospectively
in larger cohorts of equivalently treated patients. The eventual goal of refining the discov-
ery and use of clinically relevant biomarkers is the development of patient specific ES
therapeutic modalities.
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INTRODUCTION
First described by James Ewing as an endothelioma of bone
(Ewing, 1972), Ewing sarcoma (ES) was for many years primarily a
histologic diagnosis of exclusion based on its highly undifferenti-
ated, small round blue cell phenotype. Although ES presents most
commonly in bones in the pediatric and adolescent populations,
in older patients it is predominantly a soft tissue tumor (Karski
et al., 2013). Historically, tumors in specific anatomic locations or
with features suggestive of differentiation resulted in distinct diag-
noses such as Askin tumors, peripheral primitive neuroectodermal
tumor (PNET), or extraosseous ES. However, based on the identi-
fication of a common genetic lesion, and similar clinical behavior
and response to treatment, the World Health Organization now
collectively refers to these tumors as ES (Fletcher et al., 2013).
It was the advent of consistency in diagnosis that enabled coop-
erative groups worldwide to develop multi-center ES clinical trials.
Over the past three decades these trials have systematically eval-
uated and optimized local and systemic treatment protocols for
patients with ES (Rosen et al., 1974; Miser et al., 1987; Nesbit
et al., 1990; Kung et al., 1993; Craft et al., 1998; Ferrari et al.,
1998; Paulussen et al., 1998; Saylors et al., 2001). The current
standard of care for North American pediatric cooperative group
patients with localized ES was derived from two recent Phase III
clinical trials from the Children’s Oncology Group (COG) (Grier
et al., 2003; Womer et al., 2012). Patients with non-metastatic
disease receive multi-agent chemotherapy every 2 weeks as neoad-
juvant therapy before local control, which comprises surgery,
radiation or both, and then adjuvant therapy for an additional
several cycles. With this aggressive regimen, patients with local-
ized disease have event free survival (EFS) rates of around 75%.
Unfortunately, approximately 20–30% of patients present with
metastases, and these patients have drastically poorer outcomes
since systemic chemotherapy trials have not improved durable
remission rates for patients with metastatic ES (Cotterill et al.,
2000; Rodriguez-Galindo et al., 2008).
Outside of metastasis there is a large body of literature that
supports other clinical-pathologic features as markers of high-
risk disease. Increasing tumor size, decreased tumor necrosis
after neoadjuvant chemotherapy, central tumor site (axial versus
appendicular), and increasing patient age have all been impli-
cated as negative prognostic features. None of these are as sig-
nificant as the presence of metastatic disease and studies have
demonstrated variability in these individual features (Sauer et al.,
1987; Cotterill et al., 2000; Oberlin et al., 2001; Paulussen et al.,
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2001; Martin and Brennan, 2003; Bacci et al., 2004; Lin et al.,
2007; Rodriguez-Galindo et al., 2008; Lee et al., 2010). Thus,
current North American cooperative group therapeutic ES tri-
als stratify patients based solely on the presence or absence
of metastases. Furthermore, we have little insight into which
patients with localized disease are at risk for recurrence or which
patients with metastatic disease are curable with conventional
therapy. It would be very beneficial if practitioners could pre-
dict which patients are unlikely to be cured by standard therapy
so that they can be considered for treatment with novel agents
and regimens. As new agents are introduced into practice it
will also be important to introduce them rationally, prescrib-
ing them to optimal patient cohorts who will be most likely to
respond.
In an effort to advance knowledge of tumor biology and
treatment response in pediatric cancer patients the COG has
established disease-specific biology committees. The COG Ewing’s
Biology Committee consists of physicians and researchers with
expertise in ES biology, pre-clinical, and translational research,
and clinical care. One of the goals of the committee is to enable
the identification of reliable biomarkers that can predict treatment
response and outcome through the use of prospectively collected
tissues and correlative studies in concert with COG therapeu-
tic studies. This report aims to provide a concise review of the
most well-characterized prognostic biomarkers in ES, and to pro-
vide recommendations concerning design and implementation of
future biomarker studies.
BIOMARKERS AND REMARK CRITERIA
In the current era of individualized therapies and the goal of “per-
sonalized medicine,” the term biomarker is increasingly en vogue.
However, attention to the precise definitions of a biomarker, and
how the biomarker was developed, validated, and applied to clin-
ical protocols is critical. The National Institutes of Health defines
a biomarker as a characteristic that is objectively measured and
evaluated as an indicator of normal biologic processes, pathogenic
processes, or pharmacologic responses to a therapeutic interven-
tion (De Gruttola et al., 2001). The characteristics of a useful
biomarker include the following: provide a clear risk/benefit ratio
to facilitate clinical decisions, available in an efficient, and cost-
effective manner, can be assessed on easily obtainable samples,
and able to be performed on available technological platforms
(Hodgson et al., 2009).
Biomarkers can be subdivided into two types: prognostic and
predictive. The majority of biomarkers studied in ES are prognostic.
Prognostic biomarkers provide information about the outcome of
a disease following standard therapy (La Thangue and Kerr, 2011).
As discussed above, the presence of metastatic disease at diagnosis
is currently the most clinically informative prognostic biomarker
in ES. Based on knowledge of this feature (i.e., metastasis), cur-
rent protocols may augment therapy and/or add novel agents to
patients with metastatic disease in an attempt to improve out-
comes. In comparison, predictive biomarkers provide information
about the likelihood of response to a certain therapeutic modality,
such as a novel agent. This group of predictive biomarkers allows
for a more individualized approach to treatment, as it provides
direct information linking drug and tumor response (La Thangue
and Kerr, 2011). To date, these types of biomarkers are lacking
in ES.
Laboratory advances and improvements in tumor banking,
have led to a dramatic increase in studies exploring the use of bio-
markers. However, conflicting results from studies analyzing the
same biomarker often emerge. Contradictory findings may arise
from issues such as methodological differences,poor study designs,
non-standardized assays, and small sample sizes (McShane et al.,
2005). To address these issues, level of evidence (LOE) scales for
tumor marker studies were established by the American Society
of Clinical Oncology (Table 1), and these LOE scales continue
to be reevaluated and modified (Hayes et al., 1996; Simon et al.,
2009). When designed properly, prospective studies provide the
most reliable data for biomarker analysis with little to no addi-
tional validation necessary. Significant efforts to optimize the
reporting of biomarker studies have also been recently made.
The National Cancer Institute published Reporting Recommenda-
tions for Tumor Marker Prognostic Studies (REMARK) guidelines
in 2005 and updated these in 2012 (McShane et al., 2005; Alt-
man et al., 2012) (Table 2). These guidelines require that for a
biomarker study to be considered adequate, it must: (1) clearly
describe treatment modalities of all patients, (2) utilize repro-
ducible methodology, and (3) contain a well-defined and robust
biostatistical plan. In pediatric oncology, where prospective clini-
cal trials take many years to complete and require the participation
of clinicians at numerous institutions, it is imperative that prospec-
tive biomarker studies be fastidiously designed in order to ensure
that the accumulated data is adequate and interpretable.
PROGNOSTIC BIOMARKERS IN ES
Numerous studies of prognostic biomarkers in ES as well as sev-
eral comprehensive reviews of these biomarkers have recently been
published (Pinto et al., 2011; van Maldegem et al., 2012; Wagner
et al., 2012). This review focuses on four main categories: EWSR1
translocation type, cell-cycle proteins, copy number alterations
(CNAs), and sub-clinical disease measurement. Fusion type will
be discussed to demonstrate the importance of prospective eval-
uation and validation of biomarkers in the context of evolving
therapy. The remaining categories were selected for in depth dis-
cussion after consideration of REMARK criteria. In the following
sections we will highlight the features of each of these putative
biomarkers that lead us to propose that their parallel evaluation
and validation in the next series of prospective therapeutic tri-
als is warranted. Several of these, including CNAs and cell-cycle
proteins were recently discussed at a European Network for Can-
cer Research in Children and Adolescents (ENCCA) summit of 35
international experts (Kovar et al., 2012). In addition, several addi-
tional “emerging” biomarkers of potential prognostic significance
were discussed at the ENCCA summit and the reader is directed
to the published summary of these discussions for more detailed
information (Kovar et al., 2012).
EWSR1 TRANSLOCATION TYPE
The molecular hallmark of ES is a recurrent chromosomal translo-
cation involving theEWSR1 gene and one of several different genes
belonging to the ETS family (Delattre et al., 1992). In approxi-
mately 85% of these translocations, the 5′ portion of the EWSR1
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Table 1 | Levels of evidence for grading clinical utility of tumor markers.
Level Type of evidence
I Evidence from a single, high-powered, prospective, controlled study that is specifically designed to test marker or evidence from
meta-analysis and/or overview of level II or III studies. In the former case, the study must be designed so that therapy and follow-up are
dictated by protocol. Ideally, the study is a prospective, controlled randomized trial in which diagnostic and/or therapeutic clinical
decisions in one arm are determined at least in part on the basis of marker results, and diagnostic and/or therapeutic clinical decisions in
the control arm are made independently of marker results. However, study design may also include prospective but not randomized
trials with marker data and clinical outcome as primary objective.
II Evidence from study in which marker data are determined in relationship to prospective therapeutic trial that is performed to test
therapeutic hypothesis but not specifically designed to test marker utility (i.e., marker study is secondary objective of protocol).
However, specimen collection for marker study and statistical analysis are prospectively determined in protocol as secondary objectives.
III Evidence from large but retrospective studies from which variable numbers of samples are available or selected. Therapeutic aspects
and follow-up of patient population may or may not have been prospectively dictated. Statistical analysis for tumor marker was not
dictated prospectively at time of therapeutic trial design.
IV Evidence from small retrospective studies that do not have prospectively dictated therapy, follow-up, specimen selection, or statistical
analysis. Study design may use matched case—controls, etc.
V Evidence from small pilot studies designed to determine or estimate distribution of marker levels in sample population. Study design
may include “correlation” with other known or investigational markers of outcome but is not designed to determine clinical utility.
Reprinted by permission from Oxford University Press: Journal of the National Cancer Institute (Hayes et al., 1996).
gene on chromosome 22 is fused to the 3′ portion of the FLI1
gene on chromosome 11. The most common fusion type joins
exon 7 of EWSR1 with exon 6 of FLI1, also known as the type-1
fusion. However, numerous less common breakpoints between the
two genes have been identified. Furthermore, about 10% of cases
involve alternate ETS family genes as the 3′ translocation partner.
A detailed review of the various fusion types described in ES was
recently published by Sankar and Lessnick (2011).
Associations between fusion type and prognosis were observed
in the late 1990s through studies of archival tumors and outcome
data. de Alava et al. (1998) analyzed 99 patient samples and found
that patients with tumors harboring a type-1 fusion had a signifi-
cantly better overall survival compared to those with other fusion
types. The difference was observed when all patients were analyzed,
as well among those patients who presented with localized disease.
Similarly, Zoubek et al. (1996) performed a retrospective analy-
sis of 85 tumor samples from patients enrolled on the European
Cooperative ES Studies. In this study a significant reduction in
relapse rate was observed in patients with localized disease whose
tumors harbored a type-1 fusion.
In an attempt to validate these retrospective studies on prospec-
tively collected sets of tumors from equivalently treated patients,
both COG and Euro-Ewing evaluated fusion status and outcomes
in patients diagnosed between 1999 and 2007. Strikingly, these
studies failed to confirm the original findings. Reporting on 578
patients enrolled on the European EURO-E.W.I.N.G. 99 trial, Le
Deley et al. (2010) failed to observe an impact of fusion type on risk
of progression or relapse. Likewise, van Doorninck et al. studied
119 prospectively collected patient samples from two consecutive
COG trials and again failed to identify differences in clinical out-
comes based on EWSR1 fusion status. While the original finding
of fusion type as a prognostic biomarker may have been due to
the bias of retrospective studies, it is possible that the increased
intensity of current treatment regimens eliminated the impact of
EWSR1 fusion type on clinical outcome (Barr and Meyer, 2010;
van Doorninck et al., 2010).
Although variations in EWSR1 fusion partner can no longer
be considered prognostic, recent discoveries have complicated the
clinical scenario. There have been several recent reports of novel
non-EWSR1 fusions in tumors with Ewing-like features (CIC-
DUX and BCOR-CCND fusions) (Italiano et al., 2012; Pierron
et al., 2012). In the absence of data to support an alternate diagno-
sis or approach to treatment, these patients are treated according to
ES standard care or are enrolled on ES therapeutic trials. Based on
their rarity, unless outcomes for these tumors prove to be dramat-
ically different from more classical ES, it is statistically improbable
that studies of these cases will ever meet REMARK criteria for
definitive designation as prognostic biomarkers. Ideally, a better
understanding of the biologic heterogeneity of ES may offer mech-
anistic insights that ultimately direct optimal clinical care for these
variant cases.
In summary, current levels of evidence strongly suggest that
among the greater than 90% of ES tumors that harbor EWSR1
rearrangements, fusion type is no longer a reliable prognostic
marker and should not be used to stratify therapy or instruct
treatment decisions.
CELL-CYCLE PROTEINS
The cell-cycle pathway and its multiple protein components are
frequently altered in cancer. In ES, genetic alterations affecting the
pRB-dependent cell-cycle regulation pathway have been described
including deletions of both CDKN2A (INK4A/ARF) and RB1.
Kovar et al. (1997) first described CDKN2A deletions in 30% of
tumors (N = 8/27) and 52% of ES cell lines (N = 12/23) and
several retrospective studies have demonstrated an association
between CDKN2A alterations and clinical outcome in ES patients.
www.frontiersin.org June 2013 | Volume 3 | Article 141 | 3
Shukla et al. Biomarkers in Ewing sarcoma review
Table 2 | Reporting recommendations for tumor marker prognostic studies.
Guidelines for the REporting of tumor MARKer studies (REMARK)
Introduction
State the marker examined, the study objectives, and any prespecified hypotheses
Materials and methods
Patients
Describe the characteristics (e.g., disease stage or comorbidities) of the study patients, including their source and inclusion and exclusion criteria
Describe treatments received and how chosen (e.g., randomized or rule-based)
Specimen characteristics
Describe the type of biological material used (including control samples) and methods of preservation and storage
Assay methods
Specify the assay method used and provide (or reference) a detailed protocol, including specific reagents or kits used, quality control procedures,
reproducibility assessments, quantitation methods, and scoring and reporting protocols. Specify whether and how assays were performed blinded to
the study end point
Study design
State the method of case selection, including whether the study design was prospective or retrospective and whether stratification or matching
(e.g., by stage of disease or age) was used. Specify the time period from which cases were taken, the end of the follow-up period, and the median
follow-up time
Precisely define all clinical end points examined
List all candidate variables initially examined or considered for inclusion in models
Give rationale for sample size; if the study was designed to detect a specified effect size, give the target power and effect size
Statistical analysis methods
Specify all statistical methods, including details of any variable selection procedures and other model-building issues, how model assumptions were
verified, and how missing data were handled
Clarify how marker values were handled in the analyses; if relevant, describe methods used for cutpoint determination
Results
Data
Describe the flow of patients through the study, including the number of patients included in each stage of the analysis (a diagram may be helpful)
and reasons for dropout. Specifically, both overall and for each subgroup extensively examined report the numbers of patients and the number of
events
Report distributions of basic demographic characteristics (at least age and sex), standard (disease-specific) prognostic variables, and tumor marker,
including numbers of missing values
Analysis and presentation
Show the relation of the marker to standard prognostic variables
Present univariate analyses showing the relation between the marker and outcome, with the estimated effect (e.g., hazard ratio and survival
probability). Preferably provide similar analyses for all other variables being analyzed. For the effect of a tumor marker on a time-to-event outcome,
a Kaplan–Meier plot is recommended
For key multivariable analyses, report estimated effects (e.g., hazard ratio) with confidence intervals for the marker and, at least for the final model,
all other variables in the model
Among reported results, provide estimated effects with confidence intervals from an analysis in which the marker and standard prognostic variables
are included, regardless of their statistical significance
If done, report results of further investigations, such as checking assumptions, sensitivity analyses, and internal validation
Discussion
Interpret the results in the context of the prespecified hypotheses and other relevant studies; include a discussion of limitations of the study
Discuss implications for future research and clinical value
Reprinted by permission from American Society of Clinical Oncology: The Journal of Clinical Oncology (McShane et al., 2005).
Wei et al. (2000) identified CDKN2A deletions in 18% of analyzed
tumor samples (N = 7/39), while Tsuchiya et al. (2000) found
CDKN2A deletions in 17% of tumor samples (N = 4/24). Patients
in both studies were found to have worse disease-specific sur-
vival in univariate and multivariate analyses. Maitra et al. (2001)
identified CDKN2A downregulation by immunohistochemistry
in 20% of patients (N = 4/20), and this correlated with metasta-
tic disease at presentation and trended toward shortened sur-
vival. A meta-analysis examining the prognostic significance of
CDKN2A alterations in ES based on six separate studies (N = 188)
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concluded that the estimated pooled risk ratio (RR) for worse out-
come withCDKN2A alterations was 2.17 [95% confidence interval
(95% CI), 1.55–3.03; P < 0.001] and the estimated pooled RR of
metastasis at diagnosis was 2.60 (N = 164 eligible, 95% CI, 1.71–
3.97; P < 0.001) (Honoki et al., 2007). Finally, using multiplex
ligation-dependent probe amplification (MLPA), homozygous
deletion of CDKN2A was identified in 44% of cell lines (N = 4/9)
and 10% of primary tumors (N = 4/42) (Brownhill et al., 2007).
Hemizygous deletion was detected in an additional 22 and 5% of
samples, respectively. In contrast to previous reports, this study
did not identify prognostic value of CDKN2A deletions or protein
expression. However, given that only 4 patients with CDKN2A
were identified in this study, it is difficult to draw definitive con-
clusions. Based on the cumulative data, it is the opinion of this
committee that the evidence to supportCDKN2A loss as a negative
prognostic marker is strong, and worthy of prospective validation.
The potential of TP53 mutational status as a prognostic bio-
marker in ES also has been evaluated in retrospective studies. Using
immunohistochemistry, Abudu et al. (1999) detected TP53 over-
expression indicative of non-functional protein in 14% of tumor
samples (N = 7/52) and this over-expression was associated with
advanced disease at diagnosis, poorer treatment response, and
a worse overall survival. Significantly, this effect was indepen-
dent of site, local treatment, or tumor necrosis. Similarly, a study
by de Alava et al. (2000) identified TP53 over-expression based
on immunoreactivity in 11% of tumor samples (N = 6/55) and
increased p53 protein expression was found to be the strongest
prognostic factor that was associated with worse overall sur-
vival. Huang et al. (2005) reported TP53 mutations in 13.3%
of patient samples (N = 8/60), as well as CDKN2A homozygous
deletions in another 13.3% of samples (N = 8/60). TP53 muta-
tions and/or CDKN2A deletions were significantly associated with
a poor response to chemotherapy (P < 0.0001) and, in a mul-
tivariate analysis, TP53 and/or CDKN2A alteration status as a
single combined variable was identified as the most significant
prognostic factor (P < 0.001). Finally, using immunohistochem-
istry and fluorescent in situ hybridization (FISH), Lopez-Guerrero
et al. (2011) analyzed cell-cycle regulation markers in 324 cases
of ES. They reported a significant association between increased
TP53 expression and metastatic disease (P = 0.025), and worse
progression-free survival (P = 0.012) and disease-specific survival
(P = 0.006) in patients with localized disease.
In summary, compelling data from several retrospective studies
implicates alterations of TP53 and CDKN2A as negative prog-
nostic biomarkers in ES. Currently, COG and the ES Biology
Committee are performing a large-scale analysis of TP53 and
CDKN2A status in over 150 prospectively collected tumors from
patients treated on the most recent AEWS0031 therapeutic study.
Should this study confirm prior observations, analysis of these
cell-cycle regulatory proteins will become a strong candidate for
inclusion as a prognostic biomarker that can inform treatment
decisions in future clinical trials.
COPY NUMBER ALTERATIONS
Genomic instability with subsequent CNAs have been well-
documented in ES and these alterations have been recently
reviewed by Jahromi et al. (2011). The recurrent CNAs most
commonly described to be associated with outcome are summa-
rized in Table 3 along with reference to the primary manuscripts.
The most commonly reported CNAs in ES are trisomy of chromo-
some 8, trisomy of chromosome 12, and gain of chromosome 1q.
The technology to measure these CNAs has improved throughout
the years, and likewise so has the ability to detect and correlate
CNA with clinical outcome. Using a variety of platforms, sev-
eral recurring regions of gains and losses with clinical relevance
have been described. However, these retrospective studies use dif-
ferent approaches to identify CNAs among varying number of
patients leading to different trends and degrees of association. A
prospective analysis of CNAs and clinical outcome has not yet been
undertaken.
In summary, independent studies of both small and large tumor
cohorts have identified individual and global patterns of CNAs
as putative prognostic biomarkers in ES. We anticipate that the
continued improvement in next generation sequencing platforms
will allow for greater characterization of structural variations in
tumors, and will generate even more data to test associations
between CNAs and clinical outcome. It is the recommendation
of this committee that tumor and germline DNA be collected
from all patients registered on future therapeutic studies of ES
in order that CNAs and other genetic mutations can be evalu-
ated as prognostic and predictive biomarkers in homogeneously
treated patients. To that end, COG has discussed the prospective
incorporation of CNA and genomic analysis in their upcoming ES
trial for relapsed/refractory patients.
SUB-CLINICAL DISEASE
Assessment of minimal residual disease (MRD) has been estab-
lished as a critical part of therapeutic decision making in child-
hood acute lymphoblastic leukemia (Biondi et al., 2000; Borowitz
et al., 2008). Standardized methodologies and MRD assessment
time points have been incorporated into COG and other coop-
erative group lymphoblastic leukemia protocols, and serve as
prognostic biomarkers for patient risk stratification. As detailed
below, attempts to validate methodologies and prognostic cor-
relations for sub-clinical disease detection in ES have primarily
used reverse-transcriptase polymerase chain reaction (RT-PCR)
and flow cytometry.
RT-PCR
RT-PCR assays for sub-clinical disease are designed to identify
pathognomonic ES related fusion transcripts in blood and/or bone
marrow as evidence of occult micrometastatic disease or persis-
tent disease following systemic therapy. Through serial dilution
experiments of established ES cell lines, this methodology was
proven to have sufficient sensitivity to detect a single tumor cell
among 106 normal cells (Peter et al., 1995; Pfleiderer et al., 1995;
West et al., 1997). The largest published study examined EWSR1-
FLI1 and EWSR1-ERG transcript levels in the bone marrow and
peripheral blood taken at the time of diagnosis of ES in 172
patients, 140 of whom were enrolled on French Society of Pediatric
Oncology (SFOP) protocols and therefore received similar therapy
(Schleiermacher et al., 2003). RT-PCR positive bone marrow sam-
ples were identified in 27% of evaluated patients (N = 36/131),
and 19% of patients (N = 18/92) with non-metastatic disease
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Table 3 | Recurrent CNAs and outcome correlations in Ewing sarcoma studies.
Region Technology Total with CNA EFS (%) Significance OS (%) Significance Study
1p36.3 loss Cytogenetics and
FISH
9/51 (18%) 17 vs. 81 P =0.004 Hattinger et al. (1999)
1q21-q22 gain CGH 5/20 (25%) – – 50 vs. 78 P =0.57 (trend) Armengol et al. (1997)
G-banded
karyotype
3/20 (15%) – – 0 vs. 61 NA Kullendorff et al. (1999)
CGH 5/28 (18%) 40 vs. 59 P =0.30 (trend) 40 vs. 60 P =0.45 (trend) Tarkkanen et al. (1999)
CGH 21/67 (31%) – – 41 vs. 87* P =0.32 (trend,
multivariate)
Mackintosh et al. (2012)
6p21.1 gain CGH 3/28 (11%) 0 vs. 63 P =0.04 0 vs. 64 P =0.004 Tarkkanen et al. (1999)
8 gain CGH 7/20 (35%) – – 50 vs. 84 P =0.16 (trend) Armengol et al. (1997)
CGH 10/28 (36%) 40 vs. 65 P =0.16 (trend) 45 vs. 63 P =0.39 (trend) Tarkkanen et al. (1999)
Cytogenetics and
FISH
10/21 (48%) 90 vs. 60 P =0.1528 (trend) – – Zielenska et al. (2001)
SNP Microarray
(MIP)
15/40 (38%) 35 vs. 80 P =0.0059 26 vs. 100 P =0.00038 Jahromi et al. (2012)
12 gain CGH 5/20 (25%) 50 vs. 78 P =0.30 (trend) Armengol et al. (1997)
CGH 3/28 (11%) 33 vs. 59 P =0.36 (trend) 67 vs. 55 P =0.67 (trend) Tarkkanen et al. (1999)
Cytogenetics and
FISH
6/16 (38%) 50 vs. 94 P =0.0751 (trend) Zielenska et al. (2001)
16q loss CGH 11/52 (21%) – – NA P = 0.0006 Ozaki et al. (2001)
SNP Microarray
(MIP)
4/40 (10%) 25 vs. 70 P =0.11 (trend) 50 vs. 74 P =0.26 (trend) Jahromi et al. (2012)
20 gain Cytogenetics 10/75 (13%) 16 vs. 57 P =0.006 30 vs. 59 P = 0.008 Roberts et al. (2008)
SNP Microarray
(MIP)
7/40 (18%) 30 vs. 68 P =0.012 0 vs. 79 P = 0.00013 Jahromi et al. (2012)
Complex G-banded
karyotype
3/20 (15%)** – – 0 vs. 61 NA Kullendorff et al. (1999)
Cytogenetics and
FISH
9/22 (41%)*** 44 vs. 100 P =0.034 – – Zielenska et al. (2001)
CGH 13/48 (27%)**** – – 15 vs. 50 P = 0.009 Ozaki et al. (2001)
CGH 12/25
(48%)*****
– – 25 vs. 80 P = 0.034
(multivariate)
Ferreira et al. (2008)
Cytogenetics 22/75 (29%)** 29 vs. 50 P =0.08 (trend) 47 vs. 58 P = 0.05 Roberts et al. (2008)
CGH 11/23
(48%)*****
20 vs. 42 P =0.049 30 vs. 67 P = 0.030 Savola et al. (2009)
SNP Microarray
(MIP)
20/40
(50%)*****
58 vs. 68 P =0.48 (discrete)
P =0.017
(continuous)
52 vs. 93 P = 0.027
(discrete)
P = 0.00005
(continuous)
Jahromi et al. (2012)
Multifactor Copy
Number (MCN)-index
SNP Microarray
(MIP)
N =19/40
(48%)******
40 vs. 83 P =0.013 39 vs. 100 P = 0.00013 Jahromi et al. (2012)
*Cumulative Survival.
**>50 chromosomes.
***≥1 structurally rearranged chromosomes.
****≥5 CNAs.
*****>3 CNAs.
******MCN-index: ≥1 CNA in 20q13.2 gain, 20q13.13 gain, MYC gain, 16q24.1 loss, 16q23.3-24.1 loss, Trisomy 5, Trisomy 8, Trisomy 20.
NA=Not analyzed.
MIP=Molecular Inversion Probe.
The bold font represent significant studies with p-value less than or equal to 0.05.
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at presentation. Circulating transcripts were identified in 20%
of patients (N = 29/144) at diagnosis, and were more frequently
observed in patients with large tumor burdens. In patients with
localized disease, RT-PCR positivity in bone marrow and periph-
eral blood correlated with significantly poorer outcomes. In con-
trast, a study of peripheral blood samples from 26 children was
unable to identify a significant progression-free survival difference
in patients with detectable fusion transcript at diagnosis (Avigad
et al., 2004). However, this study suggested that identification of
circulating transcript during disease follow-up was predictive of
recurrence. Finally, Zoubek et al. (1998) examined bone marrow
samples from 35 newly diagnosed patients. Transcript was detected
in 30% of patients (N = 7/23) with localized disease, 50% of
patients (N = 3/6) with isolated pulmonary metastases, and 100%
of patients (N = 6/6) with bone metastases. However, the study
did not establish a correlation between marrow positivity for ES
transcript and progression-free disease. Results of other smaller
studies have been recently summarized by Wagner et al. (2012).
To rigorously address whether the detection of circulating
tumor transcript is of prognostic significance, the multi-center
European EURO-E.W.I.N.G. 99 trial prospectively collected bone
marrow samples for over 10 years. As the first large prospective
trial examining sub-clinical disease via RT-PCR in ES patients, the
findings of this study will be critical to evaluate the feasibility and
usefulness of this modality as a biomarker for ES. Based on our
own experience with a much smaller cohort of patients in COG we,
as a committee, are skeptical that RT-PCR-based assays will be clin-
ically optimal for prognostication and treatment stratification. We
base this assertion on our combined observations regarding issues
of technical reproducibility of the assay between individual labo-
ratories, and the technical expertise required to consistently obtain
sufficient quality RNA for valid and reliable RT-PCR analysis.
Although these issues could be addressed with the establishment
of a central College of American Pathologists (CAP)-Clinical Lab-
oratory Improvement Act (CLIA)-certified reference laboratory,
the issue of RNA degradation in sample shipments would remain.
In addition, RT-PCR-based analysis requires knowledge of the pre-
cise breakpoint. With the increasing use at many COG institutions
of closed needle biopsy for diagnostic tissue collection and flu-
orescence in situ hybridization (FISH) for molecular diagnosis,
isolation of quality RNA has become less practical. Feasibility will
only diminish as additional rare non-EWSR1 translocations are
identified.
In summary, although of potential prognostic significance,
technical and logistic realities regarding tissue collection and RNA-
based studies of blood and bone marrow specimens significantly
diminish this committee’s enthusiasm for RT-PCR analysis of
sub-clinical disease in routine clinical practice. Should the afore-
mentioned Euro-Ewing study validate RT-PCR of bone marrow
as a significant prognostic variable, this issue will need to be re-
addressed. At such time, consideration would need to be given
to optimizing collection and submission of quality RNA and to
creation of a CAP-CLIA certified COG reference laboratory.
Flow cytometry
Recently, flow cytometric approaches have been used to identify
sub-clinical disease in ES (Dubois et al., 2010; Ash et al., 2011).
These assays use the cell-surface glycoprotein CD99 to identify
tumor cells. Dubois et al. (2010) used a gating strategy to identify
CD99+/CD45− cells in normal peripheral blood samples spiked
with varying titrations of cultured ES cells. They were able to iden-
tify one tumor cell among 5× 105 peripheral blood mononuclear
cells. Ash et al. (2011) used a similar gating strategy and identi-
fied ES cells that were CD99+/CD90+/CD45−. Diagnostic bone
marrow samples from 46 ES patients, including 35 with localized
disease, were examined. Tumor cells were identified in all 46 diag-
nostic marrow samples, ranging from 0.001–0.4% positivity. Ten
control marrow samples from patients without malignancies were
all negative. Furthermore, they identified high CD56 expression
on the tumor cells as a significant poor prognostic factor.
Flow cytometric based platforms have several practical advan-
tages over RT-PCR. Flow cytometric assays require significantly
less labor, and are easier to standardize across different centers.
For central laboratories, sample shipment does not carry the same
degree of concern about degradation as RNA-based assays. Finally,
unlike RT-PCR in which knowledge of the precise fusion type is
required, a single flow cytometric assay could potentially be used
for all patients.
These two initial studies of flow cytometry for sub-clinical dis-
ease detection confirm feasibility of the approach and provide
preliminary support for the potential prognostic significance of
circulating tumor cells. Studies are now underway to validate
these findings within the context of current and planned COG
studies. Specifically, bone marrow samples are being prospectively
analyzed from newly diagnosed patients through the AEWS07B1
banking study and on patients with recurrent disease through both
AEWS07B1 and through ADVL1221.
OTHER STUDIES
Many other prognostic markers in ES have been studied and asso-
ciated with significant differences in outcome (Table 4). Unfortu-
nately, the reporting standards of most of these studies do not
fulfill REMARK criteria, with treatment variability and inade-
quate sample size being frequent problems. Further validation of
the most promising of these studies is essential. As a first step,
retrospective analysis of larger cohorts of prospectively collected
and banked tumor tissues should be used to validate early find-
ings in independent patient cohorts. Putative biomarkers that hold
up to expanded retrospective-prospective analysis could then be
considered for inclusion and validation in parallel with future
therapeutic trials. Ideally, biomarkers that advance to prospec-
tive analysis will be measureable by accessible and straightforward
assays that are amenable to evaluation at multiple, non-specialized
sites. For example assays that require immunohistochemistry of
fixed tumor specimens or analysis of peripheral blood would be
preferred to those that require significant technical expertise or
fresh tissue.
TARGETED AGENTS FOR ES: THE NEED FOR PREDICTIVE
BIOMARKERS
A number of biological targets and potentially promising novel
agents have been identified for ES, many of which were discussed
at the aforementioned ENCCA summit (Kovar et al., 2012). For
the purpose of this discussion, we will focus on two proteins which
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Table 4 | Recent studies examining potential Ewing sarcoma biomarkers.
Study Methodology Findings P -value
Ohali et al.
(2003)
Analysis of telomerase activity in post-therapy peripheral
blood samples of 26 patients
High telomerase activity is correlated with
poorer PFS
P <0.0001
Fuchs et al.
(2004)
Immunohistochemical analysis of vascular endothelial
growth factor (VEGF) expression in 31 diagnostic tumor
samples
Positive VEGF expression is correlated with
poorer OS
P =0.0047
Kreuter et al.
(2006)
Immunohistochemical analysis of vascular endothelial
growth factor-A (VEGF-A) expression in 40 diagnostic tumor
samples
Positive VEGF-A expression is correlated with
improved OS
P =0.013
Cheung et al.
(2007)
Quantitative RT-PCR analysis of six-transmembrane
epithelial antigen of the prostate 1 (STEAP1), cyclin D1
(CCND1), and NKX2-2 transcription factor (NKX2-2) in 35
histologically normal diagnostic bone marrow samples
Increased marrow expression of STEAP1,
CCND1or NKX2-2 is correlated with poorer
OS
P =0.0001
Yabe et al.
(2008)
Immunohistochemical analysis of papillomavirus binding
factor (PBF) expression in 20 primary tumor samples
Over-expression (grade+++) of PBF is
correlated with poorer OS
P <0.05
Kikuta et al.
(2009)
Immunohistochemical analysis of nucleophosmin (NPM)
expression in 34 primary tumor samples
Nuclear expression of NPM is correlated
with poorer OS
P <0.01
Scotlandi et al.
(2009)
Quantitative RT-PCR analysis of membrane-bound
microsomal glutathione S-transferase (MGST1) expression
in 42 primary tumor samples
Low expression of MGST1 is correlated with
improved EFS
P =0.02
Perbal et al.
(2009)
Immunohistochemical analysis of CCN3 expression in 125
primary tumor samples
High expression (grade++ or higher) of
CCN3 is correlated with poorer prognosis.
P =0.05
Luo et al.
(2009)
Immunofluorescent analysis of glutathione S-transferase
mu 4 (GSTM4) expression in 44 primary tumor samples
High expression of GSTM4 is correlated with
poorer OS
P =0.054
Zambelli et al.
(2010)
Immunohistochemical analysis of lectin galactoside-binding
soluble 3 binding protein (LGALS3BP) expression in 274
primary tumors samples
Expression of LGALS3BP is correlated with
improved EFS and OS
P =0.04 and 0.03
respectively
Meynet et al.
(2010)
Immunohistochemical analysis of Xg expression in 97
primary tumor samples
Expression of Xg is correlated with poorer
EFS and OS
P =0.02
Bennani-Baiti
et al. (2010)
Quantitative RT-PCR analysis of CXCR4 and CXCR7
expression in 49 primary tumor samples
High expression of both CXCR4 and CXCR7
is correlated with poorer OS
P =0.0161
Berghuis et al.
(2011)
Immunohistochemical analysis of T-lymphocytic infiltration in
20 primary tumor samples
Increased tumor infiltration of CD8+T-cells is
correlated with improved OS
P =0.05
Bui et al. (2011) Immunohistochemical analysis of Connexin 43 (Cx43)
expression in 36 primary tumor samples
Higher expression scores of Cx43 is
correlated poorer OS
P =0.002
Fujiwara et al.
(2011)
Immunohistochemical analysis of macrophage infiltration in
41 primary tumor samples
High levels of macrophage infiltration ([>30
CD68 cells/high-power field) is correlated
with poorer OS
P =0.0046
Machado et al.
(2012)
Immunohistochemical analysis of desmoplakin,
phosphorylated glycogen synthase kinase 3b (pGSK3β),
ZO-1, Snail, and CK8/18 in 415 primary tumor samples
Expression of desmoplakin or pGSK3β is
correlated with improved PFS. Expression of
ZO-1 or Snail is correlated with improved
overall survival. Expression of CK8/18 is
correlated with a poorer prognosis.
P =0.0044
(desmoplakin),
P =0.026 (pGSK3β),
P =0.006 (ZO-1),
P =<0.0001 (Snail),
P =0.034 (CK8/18)
Nakatani et al.
(2012)
Quantitative RT-PCR analysis of miR-34a in 49 primary
tumor samples
High expression of miR-34a is correlated
with improved EFS and OS
P =0.0001 and
0.0005 respectively
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have recently generated a great deal of interest as potential thera-
peutic targets in ES; the receptor tyrosine kinase Insulin Growth
Factor Receptor 1 (IGF-1R) and Poly (ADP-ribose) polymerase
1 (PARP1). IGF-1R is highly expressed by ES cells, and many
studies have demonstrated the importance of the IGF-1R path-
way in ES tumor models (van Valen et al., 1992; Hofbauer et al.,
1993; Scotlandi et al., 1996, 1998; Toretsky et al., 2001; Kolb et al.,
2008). Clinical application of IGF-1R directed antibodies resulted
in dramatic responses in a few patients with refractory disease
(Olmos et al., 2010b). However, in several subsequent larger tri-
als in unselected ES populations, response rates have been only
about 10%, albeit in heavily pre-treated patients (Olmos et al.,
2010a; Atzori et al., 2011; Juergens et al., 2011; Pappo et al., 2011;
Malempati et al., 2012; Tap et al., 2012). Unfortunately, serial
collections of tumor tissue following antibody therapy to eval-
uate its effect on downstream target proteins have been deemed
to be both excessively invasive and expensive (Ho and Schwartz,
2011). Therefore, whether IGF-1R targeted therapy has failed to
provide significant response rates due to a lack of intended bio-
logic activity against the tumor remains unknown. Nevertheless,
blood and serum samples from these studies have been collected,
and may yet yield helpful information in terms of biomarkers for
IGF-1R directed therapy. Furthermore, a phase 2 study of an IGF-
1R directed antibody combined with chemotherapy is ongoing
in patients with metastatic and refractory ES (NCT#00563680).
The results of these studies are eagerly anticipated by this com-
mittee and by the sarcoma clinical and research communities as a
whole.
The ability to predict whether a patient is likely to respond
to a novel agent greatly increases the chance of success of a tar-
geted therapy and fosters personalized medicine more generally.
A striking example of the benefits of a predictive biomarker is the
identification of the subset of patients with non-small cell lung
cancer (NSCLC) patients who will respond to Epidermal Growth
Factor Receptor (EGFR)-directed therapy. Activating mutations in
the EGFR gene are detectable in only a small minority of NSCLC
patients but it is these patients who selectively respond to EGFR-
directed therapy (Saintigny and Burger, 2012). Similarly, activating
mutations in KIT and PDGFRA genes in gastrointestinal stromal
tumors are predictive for clinical responses to imatinib (Hein-
rich et al., 2003). Such a biomarker does not yet exist for IGF-1R
directed therapy in ES, although recent studies have suggested
that differential expression and activation of the insulin receptor
and nuclear localization of phosphorylated IGF-1R may be useful
predictors of treatment response (Garofalo et al., 2011; Asmane
et al., 2012). These findings require validation in larger studies,
and highlight some valuable missed opportunities from earlier
trials.
The findings that only a small subset of patients with relapsed
ES respond to IGF-1R targeted monotherapy serve as a sober-
ing example of the critical need for predictive biomarkers in this
disease. As trials investigating novel agents move forward, it is
paramount that strategies that will permit evaluation of predic-
tive biomarkers be simultaneously implemented. This will enable
identification of patients who may preferentially benefit from such
interventions in the future and allow for more selective inclusion
and exclusion of patients in a manner that will lead to improved
response rates. One potential treatment modality to emerge from
recent pre-clinical investigations is PARP1 inhibition. PARP1 is a
key enzyme involved in single-strand repair of DNA (Wang et al.,
2012). In 1999, Soldatenkov et al. reported elevated PARP1 expres-
sion in ES, and regulation of PARP expression by ETS transcription
factors (Soldatenkov et al., 1999). More recently, Brenner et al.
(2012) demonstrated that ES fusion proteins interact with PARP1,
and that in vitro and in vivo models of ES are highly sensitive
to the PARP1 inhibitor Olaparib alone and in combination with
the drug temozolomide. Moreover, in a drug screening of several
hundred cancer cell lines a marked and selective susceptibility of
ES cell lines to Olaparib was also discovered (Garnett et al., 2012).
Based on these promising pre-clinical data, PARP1 inhibitors have
already entered clinical trials in adults with ES (NCT#01583543).
Since PARP1 inhibition has already been evaluated in numerous
different adult-onset tumor types, a variety of potential biomark-
ers of DNA repair currently exist [i.e.,γ-H2AX, poly(ADP-ribose)]
and could be incorporated for evaluation in future pediatric trials
(Wang and Weaver, 2011). Furthermore, assays are being devel-
oped to analyze the activity of PARP1 inhibitors in peripheral
blood cells as a potential surrogate for tumor biopsies (Ji et al.,
2011). This option would be especially appealing in pediatric
patients, in whom practitioners may be reticent to perform tumor
biopsies for exploratory biomarker studies. Due to the availabil-
ity of PARP1 inhibitors in clinical trials for adult-onset cancers,
it is possible that phase I trials for pediatric ES patients will be
developed. As these protocols are conceptualized, comprehensive
parallel testing of DNA repair markers must be included to test the
validity of these assays as predictive biomarkers. Successful valida-
tion of a predictive biomarker in concert with clinical assessment
of PARP1 inhibitor efficacy will ensure that the potential bene-
fits of these agents are suitably investigated as expeditiously as
possible.
CONCLUSION
Numerous prognostic biomarker studies for ES have been pub-
lished in recent years. Of particular interest and potentially high
clinical relevance are studies of cell-cycle proteins, sub-clinical
disease, and CNAs. All of these have demonstrated prognostic
significance in numerous retrospective studies and now need to
be validated prospectively in larger cohorts of equivalently treated
patients. The challenges in identifying and validating clinically
relevant biomarkers in ES highlight a significant hurdle for the
individualization of therapy in any rare cancer. Prospective ther-
apeutic trials with standardized treatments remain the optimum
source of biologic material and clinical correlative information
to drive successful biomarker identification. Since these trials can
take years to complete it is essential that biomarker studies be
meticulously designed and incorporated up front in therapeutic
studies. It is imperative that these studies are designed vigilantly
to maximize levels of evidence and ensure adherence to REMARK
guidelines. In addition, biomarkers that can be tested and validated
on blood or fixed tumor specimens will have the best chance of
translation into routine clinical practice. As new agents are devel-
oped, predictive biomarkers will need to be developed to assess the
benefit of these therapies and rationally design treatment strati-
fication based on likelihood of response. The choice of technical
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platforms must also be carefully considered in trials involving rare
diseases. Although characteristics such as sensitivity are impor-
tant when choosing a methodology, issues such as availability,
cost-effectiveness, and sample requirements are equally important.
Rare cancers require the participation of multiple institutions,
and it is imperative that samples from each site are similarly col-
lected and processed. Cooperative groups can play a critical role
to ensure that biomarker studies are carefully selected, rigorously
designed and, whenever possible, incorporated into therapeutic
studies.
ACKNOWLEDGMENTS
Research is supported by the Chair’s Grant U10 CA98543 and
Human Specimen Banking Grant U24 CA114766 of the Children’s
Oncology Group from the National Cancer Institute, National
Institutes of Health, Bethesda, MD, USA. Additional support for
research is provided by a grant from the WWWW (QuadW) Foun-
dation, Inc. (www.QuadW.org) to the Children’s Oncology Group.
Grant support from the following sources is also acknowledged:
NIH SPORE 1U54-CA168512 (ERL), the Daniel P. Sullivan fund,
and the Pediatric Cancer Foundation.
REFERENCES
Abudu, A., Mangham, D. C., Reynolds,
G. M., Pynsent, P. B., Tillman,
R. M., Carter, S. R., et al.
(1999). Overexpression of p53
protein in primary Ewing’s sar-
coma of bone: relationship to
tumour stage, response and prog-
nosis. Br. J. Cancer 79, 1185–1189.
doi:10.1038/sj.bjc.6690190
Altman, D. G., Mcshane, L. M.,
Sauerbrei, W., and Taube, S.
E. (2012). Reporting recom-
mendations for tumor marker
prognostic studies (REMARK):
explanation and elaboration.
BMC Med. 10:51. doi:10.1186/
1741-7015-10-51
Armengol, G., Tarkkanen, M., Viro-
lainen, M., Forus, A., Valle, J.,
Bohling, T., et al. (1997). Recur-
rent gains of 1q, 8 and 12
in the Ewing family of tumours
by comparative genomic hybridiza-
tion. Br. J. Cancer 75, 1403–1409.
doi:10.1038/bjc.1997.242
Ash, S., Luria, D., Cohen, I. J., Goshen,Y.,
Toledano, H., Issakov, J., et al. (2011).
Excellent prognosis in a subset of
patients with Ewing sarcoma iden-
tified at diagnosis by CD56 using
flow cytometry. Clin. Cancer Res.
17, 2900–2907. doi:10.1158/1078-
0432.CCR-10-3069
Asmane, I., Watkin, E., Alberti, L., Duc,
A., Marec-Berard, P., Ray-Coquard,
I., et al. (2012). Insulin-like growth
factor type 1 receptor (IGF-1R)
exclusive nuclear staining: a predic-
tive biomarker for IGF-1R mono-
clonal antibody (Ab) therapy in sar-
comas. Eur. J. Cancer 48, 3027–3035.
doi:10.1016/j.ejca.2012.05.009
Atzori, F., Tabernero, J., Cervantes, A.,
Prudkin, L., Andreu, J., Rodriguez-
Braun, E., et al. (2011). A phase I
pharmacokinetic and pharmacody-
namic study of dalotuzumab (MK-
0646), an anti-insulin-like growth
factor-1 receptor monoclonal anti-
body, in patients with advanced
solid tumors. Clin. Cancer Res.
17, 6304–6312. doi:10.1158/1078-
0432.CCR-10-3336
Avigad, S., Cohen, I. J., Zilberstein,
J., Liberzon, E., Goshen, Y., Ash,
S., et al. (2004). The predictive
potential of molecular detection in
the nonmetastatic Ewing family of
tumors. Cancer 100, 1053–1058.
doi:10.1002/cncr.20059
Bacci, G., Forni, C., Longhi, A.,
Ferrari, S., Donati, D., De Pao-
lis, M., et al. (2004). Long-
term outcome for patients with
non-metastatic Ewing’s sarcoma
treated with adjuvant and neoadju-
vant chemotherapies. 402 patients
treated at Rizzoli between 1972 and
1992. Eur. J. Cancer 40, 73–83.
doi:10.1016/j.ejca.2003.08.022
Barr, F. G., and Meyer, W. H. (2010).
Role of fusion subtype in Ewing sar-
coma. J. Clin. Oncol. 28, 1973–1974.
doi:10.1200/JCO.2009.27.2161
Bennani-Baiti, I. M., Cooper, A.,
Lawlor, E. R., Kauer, M., Ban,
J., Aryee, D. N., et al. (2010).
Intercohort gene expression co-
analysis reveals chemokine recep-
tors as prognostic indicators in
Ewing’s sarcoma. Clin. Cancer Res.
16, 3769–3778. doi:10.1158/1078-
0432.CCR-10-0558
Berghuis, D., Santos, S. J., Baelde, H.
J., Taminiau, A. H., Egeler, R. M.,
Schilham, M. W., et al. (2011).
Pro-inflammatory chemokine-
chemokine receptor interactions
within the Ewing sarcoma microen-
vironment determine CD8(+)
T-lymphocyte infiltration and affect
tumour progression. J. Pathol. 223,
347–357. doi:10.1002/path.2819
Biondi, A., Valsecchi, M. G., Seriu,
T., D’aniello, E., Willemse, M. J.,
Fasching, K., et al. (2000). Mole-
cular detection of minimal resid-
ual disease is a strong predic-
tive factor of relapse in child-
hood B-lineage acute lymphoblas-
tic leukemia with medium risk
features. A case control study
of the International BFM study
group. Leukemia 14, 1939–1943.
doi:10.1038/sj.leu.2401922
Borowitz, M. J., Devidas, M., Hunger,
S. P., Bowman, W. P., Carroll, A. J.,
Carroll, W. L., et al. (2008). Clinical
significance of minimal residual dis-
ease in childhood acute lymphoblas-
tic leukemia and its relationship to
other prognostic factors: a Chil-
dren’s Oncology Group study. Blood
111, 5477–5485. doi:10.1182/blood-
2008-01-132837
Brenner, J. C., Feng, F. Y., Han, S.,
Patel, S., Goyal, S. V., Bou-Maroun,
L. M., et al. (2012). PARP-1 inhi-
bition as a targeted strategy to
treat Ewing’s sarcoma. Cancer Res.
72, 1608–1613. doi:10.1158/0008-
5472.CAN-11-3648
Brownhill, S. C., Taylor, C., and
Burchill, S. A. (2007). Chromo-
some 9p21 gene copy number and
prognostic significance of p16 in
ESFT. Br. J. Cancer 96, 1914–1923.
doi:10.1038/sj.bjc.6603819
Bui, M. M., Han, G., Acs, G.,
Reed, D., Gonzalez, R. J., Pasha,
T. L., et al. (2011). Connexin
43 is a potential prognostic bio-
marker for Ewing sarcoma/primitive
neuroectodermal tumor. Sarcoma
2011, 971050. doi:10.1155/2011/
971050
Cheung, I. Y., Feng, Y., Danis, K.,
Shukla, N., Meyers, P., Ladanyi,
M., et al. (2007). Novel markers
of subclinical disease for Ewing
family tumors from gene expres-
sion profiling. Clin. Cancer Res.
13, 6978–6983. doi:10.1158/1078-
0432.CCR-07-1417
Cotterill, S. J., Ahrens, S., Paulussen, M.,
Jurgens, H. F., Voute, P. A., Gadner,
H., et al. (2000). Prognostic factors
in Ewing’s tumor of bone: analysis
of 975 patients from the European
Intergroup Cooperative Ewing’s Sar-
coma Study Group. J. Clin.Oncol. 18,
3108–3114.
Craft, A., Cotterill, S., Malcolm, A.,
Spooner, D., Grimer, R., Souhami,
R., et al. (1998). Ifosfamide-
containing chemotherapy in
Ewing’s sarcoma: the Second United
Kingdom Children’s Cancer Study
Group and the Medical Research
Council Ewing’s Tumor Study. J.
Clin. Oncol. 16, 3628–3633.
de Alava, E., Antonescu, C. R.,
Panizo, A., Leung, D., Meyers, P.
A., Huvos, A. G., et al. (2000).
Prognostic impact of P53 sta-
tus in Ewing sarcoma. Cancer
89, 783–792. doi:10.1002/1097-
0142(20000815)89:4<783::AID-
CNCR10>3.3.CO;2-H
de Alava, E., Kawai, A., Healey, J. H.,
Fligman, I., Meyers, P. A., Huvos, A.
G., et al. (1998). EWS-FLI1 fusion
transcript structure is an indepen-
dent determinant of prognosis in
Ewing’s sarcoma. J. Clin. Oncol. 16,
1248–1255.
De Gruttola, V. G., Clax, P., Demets,
D. L., Downing, G. J., Ellenberg, S.
S., Friedman, L., et al. (2001). Con-
siderations in the evaluation of sur-
rogate endpoints in clinical trials.
summary of a National Institutes of
Health workshop. Control. Clin. Tri-
als 22, 485–502. doi:10.1016/S0197-
2456(01)00153-2
Delattre, O., Zucman, J., Plougastel,
B., Desmaze, C., Melot, T., Peter,
M., et al. (1992). Gene fusion
with an ETS DNA-binding domain
caused by chromosome transloca-
tion in human tumours. Nature 359,
162–165. doi:10.1038/359162a0
Dubois, S. G., Epling, C. L., Teague,
J., Matthay, K. K., and Sinclair,
E. (2010). Flow cytometric detec-
tion of Ewing sarcoma cells in
peripheral blood and bone mar-
row.Pediatr. BloodCancer 54, 13–18.
doi:10.1002/pbc.22245
Ewing, J. (1972). Classics in oncol-
ogy. Diffuse endothelioma of bone.
James Ewing. Proceedings of the
New York Pathological Society, 1921.
CA Cancer J. Clin. 22, 95–98.
doi:10.3322/canjclin.22.2.95
Ferrari, S., Mercuri, M., Rosito, P.,
Mancini, A., Barbieri, E., Longhi,
A., et al. (1998). Ifosfamide and
actinomycin-D, added in the induc-
tion phase to vincristine, cyclophos-
phamide and doxorubicin, improve
histologic response and prognosis
in patients with non metastatic
Ewing’s sarcoma of the extremity. J.
Chemother. 10, 484–491.
Frontiers in Oncology | Pediatric Oncology June 2013 | Volume 3 | Article 141 | 10
Shukla et al. Biomarkers in Ewing sarcoma review
Ferreira, B. I., Alonso, J., Carrillo, J.,
Acquadro, F., Largo, C., Suela, J., et
al. (2008). Array CGH and gene-
expression profiling reveals distinct
genomic instability patterns associ-
ated with DNA repair and cell-cycle
checkpoint pathways in Ewing’s sar-
coma. Oncogene 27, 2084–2090.
doi:10.1038/sj.onc.1210845
Fletcher, C., Bridge, J., Hogendoorn, P.,
and Mertens, F. (2013). “Classifi-
cation of tumours. pathology and
genetics of tumours of soft tissue
and bone,” in World Health Orga-
nization, 4th Edn, eds C. D. M.
Fletcher, J. A. Bridge, P. Hogendoorn,
and F. Mertens (Lyon: IARC Press),
306–309.
Fuchs, B., Inwards, C. Y., and Janknecht,
R. (2004). Vascular endothelial
growth factor expression is up-
regulated by EWS-ETS oncoproteins
and Sp1 and may represent an inde-
pendent predictor of survival in
Ewing’s sarcoma. Clin. Cancer Res.
10, 1344–1353. doi:10.1158/1078-
0432.CCR-03-0038
Fujiwara, T., Fukushi, J., Yamamoto,
S., Matsumoto, Y., Setsu, N., Oda,
Y., et al. (2011). Macrophage infil-
tration predicts a poor progno-
sis for human Ewing sarcoma.
Am. J. Pathol. 179, 1157–1170.
doi:10.1016/j.ajpath.2011.05.034
Garnett, M. J., Edelman, E. J., Hei-
dorn, S. J., Greenman, C. D., Das-
tur, A., Lau, K. W., et al. (2012).
Systematic identification of genomic
markers of drug sensitivity in can-
cer cells. Nature 483, 570–575.
doi:10.1038/nature11005
Garofalo, C., Manara, M. C., Nico-
letti, G., Marino, M. T., Lollini, P.
L., Astolfi, A., et al. (2011). Effi-
cacy of and resistance to anti-IGF-
1R therapies in Ewing’s sarcoma
is dependent on insulin receptor
signaling. Oncogene 30, 2730–2740.
doi:10.1038/onc.2010.640
Grier, H. E., Krailo, M. D., Tar-
bell, N. J., Link, M. P., Fryer, C.
J., Pritchard, D. J., et al. (2003).
Addition of ifosfamide and etopo-
side to standard chemotherapy
for Ewing’s sarcoma and primitive
neuroectodermal tumor of bone.
N. Engl. J. Med. 348, 694–701.
doi:10.1056/NEJMoa020890
Hattinger, C. M., Rumpler, S., Strehl,
S., Ambros, I. M., Zoubek, A.,
Potschger, U., et al. (1999).
Prognostic impact of dele-
tions at 1p36 and numerical
aberrations in Ewing tumors.
Genes Chromosomes Cancer 24,
243–254. doi:10.1002/(SICI)1098-
2264(199903)24:3<243::AID-
GCC10>3.0.CO;2-A
Hayes, D. F., Bast, R. C., Desch, C.
E., Fritsche, H. Jr., Kemeny, N.
E., Jessup, J. M., et al. (1996).
Tumor marker utility grading sys-
tem: a framework to evaluate clin-
ical utility of tumor markers. J.
Natl. Cancer Inst. 88, 1456–1466.
doi:10.1093/jnci/88.20.1456
Heinrich, M. C., Corless, C. L.,
Demetri, G. D., Blanke, C. D.,
Von Mehren, M., Joensuu, H., et
al. (2003). Kinase mutations and
imatinib response in patients with
metastatic gastrointestinal stromal
tumor. J. Clin. Oncol. 21, 4342–4349.
doi:10.1200/JCO.2003.04.190
Ho, A. L., and Schwartz, G. K.
(2011). Targeting of insulin-like
growth factor type 1 receptor
in Ewing sarcoma: unfulfilled
promise or a promising beginning?
J. Clin. Oncol. 29, 4581–4583.
doi:10.1200/JCO.2011.38.2374
Hodgson, D. R., Whittaker, R. D.,
Herath, A., Amakye, D., and
Clack, G. (2009). Biomarkers
in oncology drug develop-
ment. Mol. Oncol. 3, 24–32.
doi:10.1016/j.molonc.2008.12.002
Hofbauer, S., Hamilton, G., Theyer,
G., Wollmann, K., and Gabor, F.
(1993). Insulin-like growth factor-
I-dependent growth and in vitro
chemosensitivity of Ewing’s sarcoma
and peripheral primitive neuroecto-
dermal tumour cell lines.Eur. J. Can-
cer 29A, 241–245. doi:10.1016/0959-
8049(93)90183-G
Honoki, K., Stojanovski, E., Mcevoy, M.,
Fujii, H., Tsujiuchi, T., Kido, A., et
al. (2007). Prognostic significance of
p16 INK4a alteration for Ewing sar-
coma: a meta-analysis. Cancer 110,
1351–1360. doi:10.1002/cncr.22908
Huang, H. Y., Illei, P. B., Zhao,
Z., Mazumdar, M., Huvos, A.
G., Healey, J. H., et al. (2005).
Ewing sarcomas with p53 muta-
tion or p16/p14ARF homozygous
deletion: a highly lethal subset
associated with poor chemore-
sponse. J. Clin. Oncol. 23, 548–558.
doi:10.1200/JCO.2005.02.081
Italiano, A., Sung, Y. S., Zhang, L.,
Singer, S., Maki, R. G., Coindre,
J. M., et al. (2012). High preva-
lence of CIC fusion with double-
homeobox (DUX4) transcription
factors in EWSR1-negative undif-
ferentiated small blue round cell
sarcomas. Genes Chromosomes Can-
cer 51, 207–218. doi:10.1002/gcc.
20945
Jahromi, M. S., Jones, K. B., and Schiff-
man, J. D. (2011). Copy num-
ber alterations and methylation in
Ewing’s sarcoma. Sarcoma 2011,
362173. doi:10.1155/2011/362173
Jahromi, M. S., Putnam, A. R.,
Druzgal, C., Wright, J., Spraker-
Perlman, H., Kinsey, M., et al.
(2012). Molecular inversion
probe analysis detects novel copy
number alterations in Ewing sar-
coma. Cancer Genet. 205, 391–404.
doi:10.1016/j.cancergen.2012.05.012
Ji, J., Kinders, R. J., Zhang, Y., Rubin-
stein, L., Kummar, S., Parchment,
R. E., et al. (2011). Modeling
pharmacodynamic response to
the poly(ADP-Ribose) poly-
merase inhibitor ABT-888 in
human peripheral blood mononu-
clear cells. PLoS ONE 6:e26152.
doi:10.1371/journal.pone.0026152
Juergens, H., Daw, N. C., Geoerger, B.,
Ferrari, S., Villarroel, M., Aerts, I., et
al. (2011). Preliminary efficacy of the
anti-insulin-like growth factor type
1 receptor antibody figitumumab in
patients with refractory Ewing sar-
coma. J. Clin. Oncol. 29, 4534–4540.
doi:10.1200/JCO.2010.33.0670
Karski, E. E., Matthay, K. K., Neuhaus,
J. M., Goldsby, R. E., and Dubois,
S. G. (2013). Characteristics and
outcomes of patients with Ewing
sarcoma over 40 years of age at
diagnosis. Cancer Epidemiol. 37,
29–33. doi:10.1016/j.canep.2012.
08.006
Kikuta, K., Tochigi, N., Shimoda, T.,
Yabe, H., Morioka, H., Toyama,
Y., et al. (2009). Nucleophosmin
as a candidate prognostic bio-
marker of Ewing’s sarcoma revealed
by proteomics. Clin. Cancer Res.
15, 2885–2894. doi:10.1158/1078-
0432.CCR-08-1913
Kolb, E. A., Gorlick, R., Houghton, P.
J., Morton, C. L., Lock, R., Carol,
H., et al. (2008). Initial testing (stage
1) of a monoclonal antibody (SCH
717454) against the IGF-1 recep-
tor by the pediatric preclinical test-
ing program. Pediatr. Blood Can-
cer 50, 1190–1197. doi:10.1002/pbc.
21450
Kovar, H., Alonso, J., Aman, P., Aryee,
D. N., Ban, J., Burchill, S. A.,
et al. (2012). The first Euro-
pean interdisciplinary Ewing sar-
coma research summit. Front. Oncol.
2:54. doi:10.3389/fonc.2012.00054
Kovar, H., Jug, G., Aryee, D. N.,
Zoubek, A., Ambros, P., Gruber,
B., et al. (1997). Among genes
involved in the RB dependent
cell cycle regulatory cascade, the
p16 tumor suppressor gene is fre-
quently lost in the Ewing family of
tumors. Oncogene 15, 2225–2232.
doi:10.1038/sj.onc.1201397
Kreuter, M., Paulussen, M., Boeckeler, J.,
Gerss, J., Buerger, H., Liebscher, C.,
et al. (2006). Clinical significance of
vascular endothelial growth factor-
A expression in Ewing’s sarcoma.
Eur. J. Cancer 42, 1904–1911.
doi:10.1016/j.ejca.2006.01.063
Kullendorff, C. M., Mertens, F., Don-
ner, M., Wiebe, T., Akerman,
M., and Mandahl, N. (1999).
Cytogenetic aberrations in Ewing
sarcoma: are secondary changes
associated with clinical out-
come? Med. Pediatr. Oncol. 32,
79–83. doi:10.1002/(SICI)1096-
911X(199902)32:2<79::AID-
MPO1>3.0.CO;2-R
Kung, F. H., Pratt, C. B., Vega, R. A.,
Jaffe, N., Strother, D., Schwenn, M.,
et al. (1993). Ifosfamide/etoposide
combination in the treatment of
recurrent malignant solid tumors
of childhood. A Pediatric Oncology
Group Phase II study. Cancer 71,
1898–1903. doi:10.1002/1097-
0142(19930301)71:5<1898::AID-
CNCR2820710529>3.0.CO;2-Q
La Thangue, N. B., and Kerr, D.
J. (2011). Predictive biomarkers:
a paradigm shift towards per-
sonalized cancer medicine. Nat.
Rev. Clin. Oncol. 8, 587–596.
doi:10.1038/nrclinonc.2011.121
Le Deley, M. C., Delattre, O., Schae-
fer, K. L., Burchill, S. A., Koehler,
G., Hogendoorn, P. C., et al. (2010).
Impact of EWS-ETS fusion type
on disease progression in Ewing’s
sarcoma/peripheral primitive neu-
roectodermal tumor: prospective
results from the cooperative Euro-
E.W.I.N.G. 99 trial. J. Clin. Oncol. 28,
1982–1988. doi:10.1200/JCO.2009.
23.3585
Lee, J., Hoang, B. H., Ziogas, A.,
and Zell, J. A. (2010). Analysis of
prognostic factors in Ewing sar-
coma using a population-based can-
cer registry. Cancer 116, 1964–1973.
doi:10.1002/cncr.24937
Lin, P. P., Jaffe, N., Herzog, C. E., Costel-
loe, C. M., Deavers, M. T., Kelly,
J. S., et al. (2007). Chemotherapy
response is an important predic-
tor of local recurrence in Ewing
sarcoma. Cancer 109, 603–611.
doi:10.1002/cncr.22412
Lopez-Guerrero, J. A., Machado, I.,
Scotlandi, K., Noguera, R., Pellin,
A., Navarro, S., et al. (2011).
Clinicopathological significance of
cell cycle regulation markers in a
large series of genetically confirmed
Ewing’s sarcoma family of tumors.
Int. J. Cancer 128, 1139–1150.
doi:10.1002/ijc.25424
Luo, W., Gangwal, K., Sankar, S.,
Boucher, K. M., Thomas, D., and
Lessnick, S. L. (2009). GSTM4 is a
microsatellite-containing EWS/FLI
target involved in Ewing’s sarcoma
www.frontiersin.org June 2013 | Volume 3 | Article 141 | 11
Shukla et al. Biomarkers in Ewing sarcoma review
oncogenesis and therapeutic resis-
tance. Oncogene 28, 4126–4132.
doi:10.1038/onc.2009.262
Machado, I., Lopez-Guerrero, J. A.,
Navarro, S., Alberghini, M., Scot-
landi, K., Picci, P., et al. (2012).
Epithelial cell adhesion molecules
and epithelial mesenchymal transi-
tion (EMT) markers in Ewing’s sar-
coma family of tumors (ESFTs). Do
they offer any prognostic signifi-
cance? Virchows Arch. 461, 333–337.
doi:10.1007/s00428-012-1288-x
Mackintosh, C., Ordonez, J. L., Garcia-
Dominguez, D. J., Sevillano, V.,
Llombart-Bosch, A., Szuhai, K., et al.
(2012). 1q gain and CDT2 overex-
pression underlie an aggressive and
highly proliferative form of Ewing
sarcoma. Oncogene 31, 1287–1298.
doi:10.1038/onc.2011.317
Maitra, A., Roberts, H., Weinberg, A.
G., and Geradts, J. (2001). Aber-
rant expression of tumor suppres-
sor proteins in the Ewing family of
tumors. Arch. Pathol. Lab. Med. 125,
1207–1212.
Malempati, S., Weigel, B., Ingle, A.
M., Ahern, C. H., Carroll, J.
M., Roberts, C. T., et al. (2012).
Phase I/II trial and pharmacoki-
netic study of cixutumumab in
pediatric patients with refractory
solid tumors and Ewing sarcoma: a
report from the Children’s Oncology
Group. J. Clin. Oncol. 30, 256–262.
doi:10.1200/JCO.2011.37.4355
Martin, R. C. 2nd, and Brennan, M.
F. (2003). Adult soft tissue Ewing
sarcoma or primitive neuroecto-
dermal tumors: predictors of sur-
vival? Arch. Surg. 138, 281–285.
doi:10.1001/archsurg.138.3.281
McShane, L. M., Altman, D. G.,
Sauerbrei, W., Taube, S. E., Gion,
M., and Clark, G. M. (2005).
Reporting recommendations for
tumor marker prognostic stud-
ies. J. Clin. Oncol. 23, 9067–9072.
doi:10.1200/JCO.2004.01.0454
Meynet, O., Scotlandi, K., Pradelli,
E., Manara, M. C., Colombo, M.
P., Schmid-Antomarchi, H., et al.
(2010). Xg expression in Ewing’s
sarcoma is of prognostic value
and contributes to tumor invasive-
ness. Cancer Res. 70, 3730–3738.
doi:10.1158/0008-5472.CAN-09-
2837
Miser, J. S., Kinsella, T. J., Triche,
T. J., Tsokos, M., Jarosinski, P.,
Forquer, R., et al. (1987). Ifos-
famide with mesna uroprotection
and etoposide: an effective regimen
in the treatment of recurrent sarco-
mas and other tumors of children
and young adults. J. Clin. Oncol. 5,
1191–1198.
Nakatani, F., Ferracin, M., Manara, M.
C., Ventura, S., Del Monaco, V.,
Ferrari, S., et al. (2012). miR-34a
predicts survival of Ewing’s sar-
coma patients and directly influ-
ences cell chemo-sensitivity and
malignancy. J. Pathol. 226, 796–805.
doi:10.1002/path.3007
Nesbit,M. E. Jr.,Gehan,E. A.,Burgert,E.
O. Jr.,Vietti,T. J.,Cangir,A.,Tefft,M.,
et al. (1990). Multimodal therapy for
the management of primary, non-
metastatic Ewing’s sarcoma of bone:
a long-term follow-up of the First
Intergroup study. J. Clin. Oncol. 8,
1664–1674.
Oberlin, O., Deley, M. C., Bui, B. N.,
Gentet, J. C., Philip, T., Terrier,
P., et al. (2001). Prognostic fac-
tors in localized Ewing’s tumours
and peripheral neuroectoder-
mal tumours: the third study
of the French Society of Paedi-
atric Oncology (EW88 study).
Br. J. Cancer 85, 1646–1654.
doi:10.1054/bjoc.2001.2150
Ohali, A., Avigad, S., Cohen, I. J.,
Meller, I., Kollender, Y., Issakov,
J., et al. (2003). Association
between telomerase activity and
outcome in patients with non-
metastatic Ewing family of tumors.
J. Clin. Oncol. 21, 3836–3843.
doi:10.1200/JCO.2003.05.059
Olmos, D., Postel-Vinay, S., Molife,
L. R., Okuno, S. H., Schuetze,
S. M., Paccagnella, M. L., et al.
(2010a). Safety, pharmacokinetics,
and preliminary activity of the
anti-IGF-1R antibody figitumumab
(CP-751,871) in patients with sar-
coma and Ewing’s sarcoma: a
phase 1 expansion cohort study.
Lancet Oncol. 11, 129–135. doi:10.
1016/S1470-2045(09)70354-7
Olmos, D., Tan, D. S., Jones, R. L.,
and Judson, I. R. (2010b). Bio-
logical rationale and current clin-
ical experience with anti-insulin-
like growth factor 1 receptor
monoclonal antibodies in treat-
ing sarcoma: twenty years from
the bench to the bedside. Can-
cer J. 16, 183–194. doi:10.1097/PPO.
0b013e3181dbebf9
Ozaki, T., Paulussen, M., Poremba,
C., Brinkschmidt, C., Rerin, J.,
Ahrens, S., et al. (2001). Genetic
imbalances revealed by compar-
ative genomic hybridization in
Ewing tumors. Genes Chromosomes
Cancer 32, 164–171. doi:10.1002/
gcc.1178
Pappo, A. S., Patel, S. R., Crowley,
J., Reinke, D. K., Kuenkele, K. P.,
Chawla, S. P., et al. (2011). R1507, a
monoclonal antibody to the insulin-
like growth factor 1 receptor, in
patients with recurrent or refractory
Ewing sarcoma family of tumors:
results of a phase II Sarcoma Alliance
for Research through Collaboration
study. J. Clin. Oncol. 29, 4541–4547.
doi:10.1200/JCO.2010.34.0000
Paulussen, M., Ahrens, S., Burdach, S.,
Craft,A., Dockhorn-Dworniczak, B.,
Dunst, J., et al. (1998). Primary
metastatic (stage IV) Ewing tumor:
survival analysis of 171 patients from
the EICESS studies. European Inter-
group Cooperative Ewing Sarcoma
Studies. Ann. Oncol. 9, 275–281.
doi:10.1023/A:1008208511815
Paulussen, M., Ahrens, S., Dunst, J.,
Winkelmann, W., Exner, G. U., Kotz,
R., et al. (2001). Localized Ewing
tumor of bone: final results of
the cooperative Ewing’s Sarcoma
Study CESS 86. J. Clin. Oncol. 19,
1818–1829.
Perbal, B., Lazar, N., Zambelli, D.,
Lopez-Guerrero, J. A., Llombart-
Bosch, A., Scotlandi, K., et al.
(2009). Prognostic relevance
of CCN3 in Ewing sarcoma.
Hum. Pathol. 40, 1479–1486.
doi:10.1016/j.humpath.2009.05.008
Peter, M., Magdelenat, H., Michon, J.,
Melot, T., Oberlin, O., Zucker, J. M.,
et al. (1995). Sensitive detection of
occult Ewing’s cells by the reverse
transcriptase-polymerase chain
reaction. Br. J. Cancer 72, 96–100.
doi:10.1038/bjc.1995.283
Pfleiderer, C., Zoubek, A., Gruber,
B., Kronberger, M., Ambros, P.
F., Lion, T., et al. (1995). Detec-
tion of tumour cells in periph-
eral blood and bone marrow from
Ewing tumour patients by RT-
PCR. Int. J. Cancer 64, 135–139.
doi:10.1002/ijc.2910640211
Pierron, G., Tirode, F., Lucchesi, C., Rey-
naud, S., Ballet, S., Cohen-Gogo, S.,
et al. (2012). A new subtype of bone
sarcoma defined by BCOR-CCNB3
gene fusion.Nat. Genet. 44, 461–466.
doi:10.1038/ng.1107
Pinto, A., Dickman, P., and Parham,
D. (2011). Pathobiologic mark-
ers of the Ewing sarcoma family
of tumors: state of the art and
prediction of behaviour. Sarcoma
2011, 856190. doi:10.1155/2011/
856190
Roberts, P., Burchill, S. A., Brownhill,
S., Cullinane, C. J., Johnston, C.,
Griffiths, M. J., et al. (2008). Ploidy
and karyotype complexity are pow-
erful prognostic indicators in the
Ewing’s sarcoma family of tumors: a
study by the United Kingdom Can-
cer Cytogenetics and the Children’s
Cancer and Leukaemia Group.Genes
Chromosomes Cancer 47, 207–220.
doi:10.1002/gcc.20523
Rodriguez-Galindo, C., Navid, F., Liu,
T., Billups, C. A., Rao, B. N.,
and Krasin, M. J. (2008). Prog-
nostic factors for local and dis-
tant control in Ewing sarcoma
family of tumors. Ann. Oncol.
19, 814–820. doi:10.1093/annonc/
mdm521
Rosen, G., Wollner, N., Tan, C., Wu,
S. J., Hajdu, S. I., Cham, W., et al.
(1974). Proceedings: disease-free
survival in children with Ewing’s
sarcoma treated with radiation
therapy and adjuvant four-drug
sequential chemotherapy. Cancer
33, 384–393. doi:10.1002/1097-
0142(197402)33:2<384::AID-
CNCR2820330213>3.0.CO;2-T
Saintigny, P., and Burger, J. A. (2012).
Recent advances in non-small cell
lung cancer biology and clini-
cal management. Discov. Med. 13,
287–297.
Sankar, S., and Lessnick, S. L.
(2011). Promiscuous part-
nerships in Ewing’s sarcoma.
Cancer Genet. 204, 351–365.
doi:10.1016/j.cancergen.2011.07.008
Sauer, R., Jurgens, H., Burgers, J.
M., Dunst, J., Hawlicek, R., and
Michaelis, J. (1987). Prognostic
factors in the treatment of Ewing’s
sarcoma. The Ewing’s Sarcoma
Study Group of the German
Society of Paediatric Oncology
CESS 81. Radiother. Oncol. 10,
101–110. doi:10.1016/S0167-8140
(87)80052-X
Savola, S., Klami, A., Tripathi, A., Niini,
T., Serra, M., Picci, P., et al. (2009).
Combined use of expression and
CGH arrays pinpoints novel candi-
date genes in Ewing sarcoma fam-
ily of tumors. BMC Cancer 9:17.
doi:10.1186/1471-2407-9-17
Saylors, R. L. III, Stine, K. C., Sullivan,
J., Kepner, J. L., Wall, D. A., Bern-
stein, M. L., et al. (2001). Cyclophos-
phamide plus topotecan in children
with recurrent or refractory solid
tumors: a Pediatric Oncology Group
phase II study. J. Clin. Oncol. 19,
3463–3469.
Schleiermacher, G., Peter, M., Oberlin,
O., Philip, T., Rubie, H., Mechinaud,
F., et al. (2003). Increased risk of sys-
temic relapses associated with bone
marrow micrometastasis and circu-
lating tumor cells in localized Ewing
tumor. J. Clin. Oncol. 21, 85–91.
doi:10.1200/JCO.2003.03.006
Scotlandi, K., Benini, S., Nanni, P.,
Lollini, P. L., Nicoletti, G., Lan-
duzzi, L., et al. (1998). Blockage of
insulin-like growth factor-I receptor
inhibits the growth of Ewing’s sar-
coma in athymic mice. Cancer Res.
58, 4127–4131.
Frontiers in Oncology | Pediatric Oncology June 2013 | Volume 3 | Article 141 | 12
Shukla et al. Biomarkers in Ewing sarcoma review
Scotlandi, K., Benini, S., Sarti, M.,
Serra, M., Lollini, P. L., Maurici,
D., et al. (1996). Insulin-like growth
factor I receptor-mediated circuit
in Ewing’s sarcoma/peripheral neu-
roectodermal tumor: a possible
therapeutic target. Cancer Res. 56,
4570–4574.
Scotlandi, K., Remondini, D., Castel-
lani, G., Manara, M. C., Nardi, F.,
Cantiani, L., et al. (2009). Overcom-
ing resistance to conventional drugs
in Ewing sarcoma and identifica-
tion of molecular predictors of out-
come. J. Clin. Oncol. 27, 2209–2216.
doi:10.1200/JCO.2008.19.2542
Simon, R. M., Paik, S., and Hayes, D.
F. (2009). Use of archived spec-
imens in evaluation of prognos-
tic and predictive biomarkers. J.
Natl. Cancer Inst. 101, 1446–1452.
doi:10.1093/jnci/djp335
Soldatenkov, V. A., Albor, A., Patel,
B. K., Dreszer, R., Dritschilo,
A., and Notario, V. (1999).
Regulation of the human poly(ADP-
ribose) polymerase promoter
by the ETS transcription fac-
tor. Oncogene 18, 3954–3962.
doi:10.1038/sj.onc.1202778
Tap, W. D., Demetri, G., Barnette, P.,
Desai, J., Kavan, P., Tozer, R., et
al. (2012). Phase II study of gan-
itumab, a fully human anti-type-1
insulin-like growth factor receptor
antibody, in patients with metasta-
tic Ewing family tumors or desmo-
plastic small round cell tumors.
J. Clin. Oncol. 30, 1849–1856.
doi:10.1200/JCO.2011.37.2359
Tarkkanen, M., Kiuru-Kuhlefelt, S.,
Blomqvist, C., Armengol, G.,
Bohling, T., Ekfors, T., et al. (1999).
Clinical correlations of genetic
changes by comparative genomic
hybridization in Ewing sarcoma
and related tumors. Cancer Genet.
Cytogenet. 114, 35–41. doi:10.
1016/S0165-4608(99)00031-X
Toretsky, J. A., Steinberg, S. M., Thakar,
M., Counts, D., Pironis, B., Parente,
C., et al. (2001). Insulin-like growth
factor type 1 (IGF-1) and IGF bind-
ing protein-3 in patients with Ewing
sarcoma family of tumors. Cancer
92, 2941–2947. doi:10.1002/1097-
0142(20011201)92:11<2941::AID-
CNCR10072>3.0.CO;2-C
Tsuchiya, T., Sekine, K., Hinohara, S.,
Namiki, T., Nobori, T., and Kaneko,
Y. (2000). Analysis of the p16INK4,
p14ARF, p15, TP53, and MDM2
genes and their prognostic impli-
cations in osteosarcoma and Ewing
sarcoma. Cancer Genet. Cytogenet.
120, 91–98. doi:10.1016/S0165-
4608(99)00255-1
van Doorninck, J. A., Ji, L., Schaub,
B., Shimada, H., Wing, M. R.,
Krailo, M. D., et al. (2010). Cur-
rent treatment protocols have elim-
inated the prognostic advantage of
type 1 fusions in Ewing sarcoma: a
report from the Children’s Oncology
Group. J. Clin.Oncol. 28, 1989–1994.
doi:10.1200/JCO.2009.24.5845
van Maldegem, A. M., Hogendoorn,
P. C., and Hassan, A. B. (2012).
The clinical use of biomarkers as
prognostic factors in Ewing sar-
coma. Clin. Sarcoma Res. 2, 7.
doi:10.1186/2045-3329-2-7
van Valen, F., Winkelmann, W., and Jur-
gens, H. (1992). Type I and type
II insulin-like growth factor recep-
tors and their function in human
Ewing’s sarcoma cells. J. Cancer
Res. Clin. Oncol. 118, 269–275.
doi:10.1007/BF01208615
Wagner, L. M., Smolarek, T. A., Sumegi,
J., and Marmer, D. (2012). Assess-
ment of minimal residual disease
in Ewing sarcoma. Sarcoma 2012,
780129. doi:10.1155/2012/780129
Wang, X., and Weaver, D. T. (2011).
The ups and downs of DNA repair
biomarkers for PARP inhibitor ther-
apies. Am. J. Cancer Res. 1, 301–327.
Wang, Z., Wang, F., Tang, T., and Guo,
C. (2012). The role of PARP1 in the
DNA damage response and its appli-
cation in tumor therapy. Front. Med.
6:156–164. doi:10.1007/s11684-012-
0197-3
Wei, G., Antonescu, C. R., De Alava,
E., Leung, D., Huvos, A. G.,
Meyers, P. A., et al. (2000).
Prognostic impact of INK4A dele-
tion in Ewing sarcoma. Cancer
89, 793–799. doi:10.1002/1097-
0142(20000815)89:4<793::AID-
CNCR11>3.0.CO;2-M
West, D. C., Grier, H. E., Swallow,
M. M., Demetri, G. D., Granowet-
ter, L., and Sklar, J. (1997). Detec-
tion of circulating tumor cells in
patients with Ewing’s sarcoma and
peripheral primitive neuroectoder-
mal tumor. J. Clin. Oncol. 15,
583–588.
Womer, R. B., West, D. C., Krailo,
M. D., Dickman, P. S., Pawel, B.
R., Grier, H. E., et al. (2012).
Randomized Controlled Trial of
interval-compressed chemotherapy
for the treatment of localized
Ewing sarcoma: a Report from
the Children’s Oncology Group.
J. Clin. Oncol. 30, 4148–4154.
doi:10.1200/JCO.2011.41.5703
Yabe, H., Tsukahara, T., Kawaguchi, S.,
Wada, T., Sato, N., and Morioka, H.
(2008). Overexpression of papillo-
mavirus binding factor in Ewing’s
sarcoma family of tumors confer-
ring poor prognosis. Oncol. Rep. 19,
129–134.
Zambelli, D., Zuntini, M., Nardi, F.,
Manara, M. C., Serra, M., Landuzzi,
L., et al. (2010). Biological indicators
of prognosis in Ewing’s sarcoma: an
emerging role for lectin galactoside-
binding soluble 3 binding protein
(LGALS3BP). Int. J. Cancer 126,
41–52. doi:10.1002/ijc.24670
Zielenska, M., Zhang, Z. M., Ng, K.,
Marrano, P., Bayani, J., Ramirez,
O. C., et al. (2001). Acquisition
of secondary structural chromo-
somal changes in pediatric Ewing
sarcoma is a probable prognos-
tic factor for tumor response
and clinical outcome. Cancer 91,
2156–2164. doi:10.1002/1097-
0142(20010601)91:11<2156::AID-
CNCR1244>3.0.CO;2-I
Zoubek, A., Dockhorn-Dworniczak, B.,
Delattre, O., Christiansen, H., Niggli,
F., Gatterer-Menz, I., et al. (1996).
Does expression of different EWS
chimeric transcripts define clini-
cally distinct risk groups of Ewing
tumor patients? J. Clin. Oncol. 14,
1245–1251.
Zoubek, A., Ladenstein, R., Windhager,
R., Amann, G., Fischmeister, G.,
Kager, L., et al. (1998). Predictive
potential of testing for bone mar-
row involvement in Ewing tumor
patients by RT-PCR: a prelimi-
nary evaluation. Int. J. Cancer 79,
56–60. doi:10.1002/(SICI)1097-
0215(19980220)79:1<56::AID-
IJC11>3.0.CO;2-F
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or financial relationships that
could be construed as a potential con-
flict of interest.
Received: 19April 2013; accepted: 19May
2013; published online: 06 June 2013.
Citation: Shukla N, Schiffman JD, Reed
D, Davis IJ, Womer RB, Lessnick SL,
Lawlor ER and The COG Ewing Sar-
coma Biology Committee (2013) Bio-
markers in Ewing sarcoma: the promise
and challenge of personalized medi-
cine. A report from the Children’s
Oncology Group. Front. Oncol. 3:141.
doi:10.3389/fonc.2013.00141
This article was submitted to Frontiers in
Pediatric Oncology, a specialty of Fron-
tiers in Oncology.
Copyright © 2013 Shukla, Schiffman,
Reed, Davis, Womer, Lessnick, Lawlor
and The COG Ewing Sarcoma Biology
Committee. This is an open-access arti-
cle distributed under the terms of the
Creative Commons Attribution License,
which permits use, distribution and
reproduction in other forums, provided
the original authors and source are cred-
ited and subject to any copyright notices
concerning any third-party graphics etc.
www.frontiersin.org June 2013 | Volume 3 | Article 141 | 13
